

CSL Limited
Shareholder Review
2007-2008





CSL Limited ABN 99 051 588 348
Shareholder Review 2007-2008

Dividends to Shareholders

On 14 April 2008, shareholders received an interim unfranked dividend of 23 cents per share. Adjusted for the 3 for 1 share split on 24 October 2007, this was an increase of 41% on the same period last year. A final dividend of 23 cents per share franked at 100% will be paid on 10 October 2008, an increase of 26% on the same period last year.

Financial Calendar

2008

13 August	Annual profit and final dividend announcement
16 September	Shares traded ex-dividend
22 September	Record date for final dividend
10 October	Final dividend paid
15 October	Annual General Meeting
31 December	Half year ends

2009

18 February	Half year profit and interim dividend announcement
10 March	Shares traded ex-dividend
16 March	Record date for interim dividend
9 April	Interim dividend paid
30 June	Year ends
19 August	Annual profit and final dividend announcement
14 September	Shares traded ex-dividend
18 September	Record date for final dividend
9 October	Final dividend paid
14 October	Annual General Meeting
31 December	Half year ends

Annual General Meeting

Wednesday 15 October 2008 at 10:00am
Function Centre, National Tennis Centre,
Melbourne Park, Batman Avenue,
Melbourne 3000

AGM Live Webcast

The Chairman's Report and the Chief Executive Officer's Report will both be webcast through CSL's web site: www.csl.com.au

Log on to the Home Page of CSL's web site and then click on the item called Annual General Meeting webcast.

Share Registry

Computershare Investor Services Pty Limited
Yarra Falls, 452 Johnston Street Abbotsford VIC 3067
Postal Address: GPO Box 2975 Melbourne VIC 3001

Enquiries within Australia: 1800 646 882
Enquiries outside Australia: +61 3 9415 4000
Investor enquiries facsimile: +61 3 9473 2500
Website: www.computershare.com.au
Email: web.queries@computershare.com.au

Highlights 2007-2008

Dear Shareholder,

Continuing robust demand for our plasma products and the strong uptake of the GARDASIL* vaccine in Australia and on international markets have combined to deliver an excellent annual result for CSL.

- Group net profit after tax from continuing operations increased 30% on the previous year to \$702 million, up 45% after adjusting for adverse foreign currency movements. Cash flow from operations grew by 49% to \$715 million;
- CSL received royalty payments of \$167 million from Merck & Co. Inc. (Merck) on international sales of the GARDASIL* vaccine and a successful Australian immunisation program has been implemented generating \$227 million.
- In February 2008, CSL launched Privigen™ in the US. This new generation 10% liquid intravenous immunoglobulin (IVIg) is set to become a driver of margin expansion and value.
- Expenditure on Research and Development increased by 18% to \$225 million.
- Following US Food and Drug Administration (FDA) approval of CSL's Afluria® influenza vaccine in September 2007, this product has been launched in the US. Capital works recently completed at our Melbourne production facility will provide the extra capacity required for significant market expansion.
- In April 2008, CSL signed a five year agreement with the Canadian Blood Service to fractionate Canadian plasma and supply a broad range of plasma products. At the same time, CSL entered into an agreement with Héma Québec to become the main supplier of bleeding disorder treatments for the Province of Quebec.
- In August 2008, CSL announced that it had signed an agreement to acquire Talecris Biotherapies Holdings Group for US\$3,100 million.

Financial Results

Financial highlights for the year ended 30 June 2008

Five Year Summary All figures are in \$A million unless stated otherwise⁽¹⁾.

	2007-08	2006-07	2005-06	2004-05	2003-04
Total revenue	3,794	3,310	2,904	2,650	1,836
Sales revenue	3,557	3,172	2,849	2,609	1,650
Research and development investment	225	191	161	141	101
Profit before income tax expense ⁽²⁾	952	774	499	410	255
Net profit ⁽²⁾	702	539	351	235	220
Capital investment	218	205	122	105	80
Total assets at 30 June	4,695	4,200	4,186	3,893	3,875
Total equity at 30 June	2,806	2,269	1,990	2,109	2,074
Net tangible assets per share at 30 June (\$) ⁽⁴⁾	3.44	2.44	2.14	2.34	2.06
Weighted average number of shares (million) ⁽⁴⁾	550	548	546	588	535
Basic earnings per share (cents) ^{(2) (4)}	127.6	98.5	64.3	39.9	41.1
Dividend per share (cents) ^{(3) (4)}	46.0	34.7	22.7	15.7	12.7


(1) The Group's results for the years ended 30 June 2008, 30 June 2007, 30 June 2006 and 30 June 2005 are reported in accordance with the Australian Equivalents to International Financial Reporting Standards (A-IFRS). The Group's results for the year ended 30 June 2004 are reported in accordance with the Group's old basis of accounting (AGAAP).

(2) Excludes recognition of the contingent consideration payable for the acquisition of Aventis Behring and the profit after tax from discontinued operations for years ended 30 June 2006 and 30 June 2005.


(3) Excludes special dividend of 10 cents for the year ended 30 June 2005.

(4) Restated for the years ended 30 June 2007, 30 June 2006, 30 June 2005 and 30 June 2004 following the 3 for 1 share split undertaken on 24 October 2007.


CSL Total Revenue
(\$A millions)




CSL Profit Before Interest and Tax⁽²⁾
(\$A millions)




CSL Net Profit⁽²⁾
(\$A millions)




CSL R&D Investment
(\$A millions)



CSL Group Sales by Region 2007-08



CSL Group Total Revenue by Major Products 2007-08



Board of Directors



Elizabeth Alexander
Chairman



Brian McNamee
Chief Executive Officer
and Managing Director



Tony Cipa
Finance Director



John Akehurst



Ian Renard



Maurice Renshaw



Kenneth Roberts



Professor John Shine



David Simpson

Executive Management Group



Dr Brian McNamee
Chief Executive Officer
and Managing Director



Antoni M Cipa
Finance Director



Peter Turvey
Company Secretary
and General Counsel



Peter Turner
President
CSL Behring



Jeff Davies
President
CSL Bioplasma



Mary Sontrop
President
CSL Biotherapies



Dr Andrew Cuthbertson
Chief Scientific Officer



Alison von Bibra
General Manager
Human Resources



Paul Walton
Senior Vice President
Corporate Development

Our Businesses

CSL Behring

CSL Behring is a global leader in biotherapies with the broadest range of quality products in our industry and substantial markets in the US, Europe and Japan.

CSL Behring products replace missing proteins in the blood and are indicated for the treatment of rare diseases such as haemophilia and other coagulation disorders, primary immune deficiencies and inherited respiratory disease.

Our products also prevent Rh-factor problems in newborns, speed recovery from heart surgery and help victims of shock and burns recover faster.

CSL Bioplasma

CSL Bioplasma provides plasma fractionation services in Melbourne under contracts with Australia, New Zealand, Hong Kong, Malaysia, Singapore, and Taiwan. We market commercial plasma products in Asia (excluding Japan) and operate an immunohaematology blood grouping business in Australia.

CSL Biotherapies

CSL Biotherapies manufactures and markets vaccines and pharmaceutical products in Australia and New Zealand and is responsible for international sales of influenza vaccines. In-licensed pharmaceutical products include vaccines and a range of neurological, cardio-thoracic, dermatological, analgesic, urological, allergy and emergency products.

New Product Development

CSL invests in the development of protein-based medicines to treat serious human illnesses. Most of our licensed medicines are purified from human plasma or made from traditional sources, like our influenza vaccines. CSL is also increasing investment in the capabilities required to develop future products using recombinant DNA technology.

Global research and development activities support CSL's core businesses and three other main areas of new product development:

- Replacement therapies that build on our plasma products portfolio;
- Therapeutic proteins based on recombinant proteins and antibodies;
- Vaccines that use our proprietary ISCOMATRIX® adjuvant and/or our influenza vaccine capabilities.

Corporate Directory

Registered Head Office

CSL Limited

45 Poplar Road
Parkville
Victoria 3052
Australia

Phone: +61 3 9389 1911

Fax: +61 3 9389 1434

www.csl.com.au

Share Registry

Computershare Investor Services Pty Limited

Yarra Falls
452 Johnston Street
Abbotsford VIC 3067

GPO Box 2975

Melbourne
Victoria 3001

Enquiries within Australia: 1800 646 882

Enquiries outside Australia: +61 3 9415 4000

Investor enquiries facsimile: +61 3 9473 2500

Email: web.queries@computershare.com.au

Website: www.computershare.com.au

Auditors

Ernst & Young

Ernst & Young Building
8 Exhibition Street
Melbourne
Victoria 3000

GPO Box 67

Melbourne Victoria 3001

Phone: +61 3 9288 8000

Fax: +61 3 8650 7777

Further Information

For further information about the Company and its operations, refer to the Company's announcements to the Australian Securities Exchange and the Company's website:

www.csl.com.au